71265-20-8

Basic information

• Product Name: Benzenamine, 3-ethyl-N-methyl-
• CAS NO: 71265-20-8
• Molecular Formula: C9H13N
• Molecular Weight: 135.209
• Mol File: 71265-20-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenamine, 3-ethyl-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 3-ethyl-N-methyl-(71265-20-8)
• EPA Substance Registry System: Benzenamine, 3-ethyl-N-methyl-(71265-20-8)

Safety Data

• Hazardous Substances Data: 71265-20-8(Hazardous Substances Data)

Upstream product

• 289714-91-6 1-[3-(methylamino)phenyl]ethanol 
• 187867-35-2 3-ethyl-N-(tert-butoxycarbonyl)aniline 
• 67-56-1 methanol 
• 7369-50-8 3-ethylnitrobenzene 
• 587-02-0 m-ethylaniline 
• 2454-37-7 3-(1-hydroxyethyl)aniline 
• 544451-34-5 N-(3-Ethyl-phenyl)-2,2,2-trifluoro-acetamide 
• 64-17-5 ethanol 

Downstream Products

• 590393-17-2 C₂₅H₃₇N₃O 

Relevant articles and documents

Synthesis and Evaluation of PPARδAgonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis

We synthesized a directed library of compounds to explore the structure-activity relationships of peroxisome proliferator-activated receptor δ(PPARδ) activation relative to mesenchymal stem cell (MSC) osteogenesis. Our scaffold used para-substituted cinnamic acids as a polar headgroup, a heteroatom and heterocycle core connecting units, and substituted phenyl groups for the lipophilic tail. Compounds were screened for their ability to increase osteogenesis in MSCs, and the most promising were examined for subunit specificity using a quantitative PPAR transactivation assay. Six compounds were selected for in vivo studies in an ovariectomized mouse model of human postmenopausal osteoporosis. Four compounds improved bone density in vivo, with two (12d and 31a) having activity comparable to that of GW0742, a well-studied PPARδ-selective agonist. 31a (2-methyl-4-[N-methyl-N-[5-methylene-4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole]]aminocinnamic acid) had the highest selectivity for PPARδcompared to other subtypes, its selectivity far exceeding that of GW0742. Our results confirm that PPARδis a new drug target for possible treatment of osteoporosis via in situ manipulation of MSCs.

Expedient stereospecific Co-catalyzed tandem C-N and C-O bond formation of: N -methylanilines with styrene oxides

Cobalt(ii)-catalyzed stereospecific coupling of N-methylanilines with styrene oxides is developed via tandem C-N and C-O bond formation using tert-butyl hydroperoxide (TBHP) as an oxidant. Optically active epoxide can be reacted with high optical purity.

Preparation of substituted guanidines

A process for the preparation of a substituted guanidine by reacting a substituted cyanamide with ammonia or a substituted amine in the presence of a Lewis acid catalyst. Also disclosed is a process for the preparation of a tri-substituted guanidine by re